Research Analysts Set Expectations for Cryoport Q1 Earnings

Cryoport, Inc. (NASDAQ:CYRX) – Roth Capital cut their Q1 2025 earnings per share (EPS) estimates for Cryoport in a research note issued to investors on Wednesday, March 5th. Roth Capital analyst R. Baldry now forecasts that the company will post earnings of ($0.34) per share for the quarter, down from their previous estimate of ($0.32). The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Cryoport’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.30) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.29) EPS.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same period last year, the firm posted ($0.29) earnings per share.

A number of other brokerages have also weighed in on CYRX. Roth Mkm lowered their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Wednesday. Finally, Guggenheim assumed coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 target price on the stock. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Price Performance

Shares of NASDAQ:CYRX opened at $6.66 on Friday. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport has a twelve month low of $4.58 and a twelve month high of $20.10. The stock’s 50 day moving average is $7.31 and its 200-day moving average is $7.62. The firm has a market capitalization of $329.21 million, a price-to-earnings ratio of -1.97 and a beta of 1.59.

Institutional Investors Weigh In On Cryoport

Several institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. grew its holdings in Cryoport by 0.4% during the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after buying an additional 1,512 shares in the last quarter. Rhumbline Advisers grew its holdings in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock worth $492,000 after buying an additional 1,764 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after purchasing an additional 2,120 shares during the period. Nebula Research & Development LLC grew its stake in Cryoport by 21.6% in the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock valued at $97,000 after purchasing an additional 2,207 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Cryoport by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock valued at $3,144,000 after purchasing an additional 2,226 shares during the period. Institutional investors own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.